Cutting-edge advancements in traceability technology for enhanced tracking and transparency

Hiren Rathod, Regional Account Director – West, North & Madhya Pradesh, Optel Group, delivered an insightful presentation at Ahmedabad Pharma Summit 2025, highlighting the company’s traceability solutions for the pharma sector. 

Tracing Optel’s journey since its inception as a vision inspection system provider, Rathod outlined the company’s evolution into a comprehensive traceability solutions provider for pharma. He elaborated on Optel’s three key verticals: Op-Chain (carbon traceability and ESG intelligence), TracSev (track and trace solutions for L1-L3), and Verify Brand (L4 enterprise-level solutions).

Rathod discussed Optel’s global footprint, with operations across Canada, Europe, South America, and India.

The session provided an in-depth look at Optel’s integrated solutions, including hardware integration, line control, plant servers, and enterprise-level serial number generation and reporting. Notably, Optel’s L4 solution enables seamless reporting to government portals globally without per-serial number charges, offering pharma companies transparency and cost efficiency.

Highlighting recent innovations, Rathod showcased solutions for carton and bottle packaging lines, emphasising tamper-evident packaging, serialisation, aggregation, and the introduction of a combo system that integrates tamper-evident, printing, and checkweighing in a single unit. 

A key highlight was Optel’s new Vial Mislabeling Prevention and Seal Defect Inspection Solution, aimed at enhancing patient safety by preventing labeling errors in injectable products. Through innovative printing and inspection technologies, the system ensures product integrity even at high operational speeds. 

The session concluded with Rathod reinforcing that Optel can help pharma firms to advance quality assurance through tablet inspection systems and help them to flexible integrate into existing production lines.

Ahmedabad Pharma Summit 2025Hiren RathodOptel Grouppharma companies
Comments (0)
Add Comment